online-thrilokyavijaya-book-pdf-version-1

01.05.2020 Views

f;jk fldgiuQ,dY%o Dalton W.S., Martz R., Lemberger L., Rodda B.E. & R.B. Forney. 1976.Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. ClinicalPharmacology Therapeutics 19(3):300–309.o Davis J.P. & H.H. Ramsey. 1949. Antiepileptic Action of Marijuana-ActiveSubstances. Federal Proceedings 8:284–285.o Dewey W.L. 1986. Cannabinoid pharmacology. Pharmacological Reviews 38:151–178.o Di Marzo V. 2006. A brief history of cannabinoid and endocannabinoidpharmacology as inspired by the work of British scientists. Trends inPharmacological Sciences 27: 134–140.o Diaz J.L. 1977. Ethnopharmacology of sacred psychoactive plants used bythe Indians of Mexico. Annual Review of Pharmacology and Toxicology17:647.o Dwarakanath C. 1965. Use of opium and cannabis in the traditional systemsof medicine in India. Bulletin of Narcotics 17:15–19.o El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D.,Khan I., ElSohly M. & S. Ross. 2010. Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa(L). Pharmacology Biochemistry and Behavior 95(4):434–442.o Elsohly M.A. & D. Slade. 2005. Chemical constituents of marijuana: thecomplex mixture of natural cannabinoids. Life Sciences 78(5):539–548.o Fernandez-Ruiz J. et al. 2007. Cannabinoid CB2 receptor: a new target forcontrolling neural cell survival? Trends in Pharmacological Science 28:39–45.o Fernandez-Ruiz J., Pazos M.R., Garcia-Arencibia M., Sagredo O. & J.A. Ramos.2008. Role of CB2 receptors in neuroprotective effects of cannabinoids.Molecular Cellular and Endocrinology 286:91–96.o Gaoni Y. & R. Mechoulam. 1964. Isolation, structure and partial synthesisof an active constituent of Hashish. Journal of American Chemical Society86:1646–1647.o Gerard C., Mollereau C., Vassart G. & M. Parmentier. 1990. Nucleotide sequenceof a human cannabinoid receptor cDNA. Nucleic Acids Research 18:7142.o Giron L.M., Freire V., Alonzo A. & A. Caceres. 1991. Ethnobotanicalsurvey of the medicinal flora used by the Caribs of Guatemala. Journal ofEthnopharmacology 34(2/3):173–187.o Goutopoulos A. & A. Makriyannis. 2002. From cannabis to cannabinergics:new therapeutic opportunities. Pharmacology & Therapeutics 95:103–117.o Grierson G.A. 1894. The hemp plant in Sanskrit and Hindi literature. IndianAntiquary September 260–262.o Hampson A.J., Grimaldi M., Axelrod J. & D. Wink. 1998. Cannabidiol andDelta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedingsof National Academy of Sciences in USA 95(14):8268–8273.341

jika; fiak je,swx.ff;%f,dalHúchd342o Hollister L.E. 1986. Health aspects of cannabis. Pharmacological Reviews38,1–20.o Hong, C.Y., D.M. Chaput de Saintonge, P. Turner & J.W. Fairbairn. 1982.Comparison of the inhibitory action of delta-9-tetrahydrocannabinol andpetroleum spirit extract of herbal cannabis on human sperm motility. HumanToxicology 1:151–154.o Howlett A.C. & R.M. Fleming. 1984. Cannabinoid inhibition of adenylatecyclase. Pharmacology of the response in neuroblastoma cell membranes.Molecular Pharmacology 26:532–538.o Howlett A.C. 1984. Inhibition of neuroblastoma adenylate cyclase bycannabinoid and nantradol compounds. Life Sciences 35:1803–1810.o Howlett A.C. 1985. Cannabinoid inhibition of adenylate cyclase. Biochemistryof the response in neuroblastoma cell membranes. Molecular Pharmacology27:429–436.o Howlett A.C., Champion T.M., Wilken G.H. & R. Mechoulam. 1990.Stereochemical effects of 11-OH-Δ 8-tetrahydrocannabinol-dimethylheptylto inhibit adenylate cyclase and bind to the cannabinoid receptor.Neuropharmacology 29:161–165.o Jain, S.P. and H.S. Puri. 1984. Ethnomedical plants of Jaunsar–Bawar Hills,Uttar Pradesh, India. Journal of Ethnopharmacology 12(2):213–222.o Kala C.P., Farooquee N.A. & U. Dhar. 2004. Prioritization of medicinal plantson the basis of available knowledge, existing practices and use value status inUttaranchal, India. Biodiversity Conservation 13:453-469.o Katona I. & T.F. Freund. 2012. Multiple functions of endocannabinoidsignaling in the brain. Annual Reviews of Neurosciences 35:529–558.o Kaufman J., Allen J.R. & L.J. West. 1969. Runaways, Hippies and Marijuana.American Journal of Psychiatry 126:717-720.o King A.B. & D.R. Corven. 1969. Effect of intravenous injection of Marijuana.Journal of American Medical Association 215:724-725.o King F.W. 1969. Marijuana and LSD usage among male college students:prevalence rate, frequency and self-estimates of future use. Psychiatry32:265-276.o Kirilly E., Gonda X. & G. Bagdy. 2012. CB1 receptor antagonists: newdiscoveries leading to new perspectives. Acta Physiologica 205:41–60.o Kraft B. & H.G. Kress. 2004. Cannabinoids and the immune system of men,mice and cells. Schmerz 18(3):203–210.o Krejci Z., M. Horak & F. Santavy. 1958. Constitution of the cannabidiolicacid, M.P.133, isolated from Cannabis sativa. Acta University Palacki OlomucFaculty of Medicine 16:9.o Lal S.D. & B.K. Yadav. 1983. Folk medicine of Kurushetra District (Haryana),India. Economic Botany 37(3):299–305.

f;jk fldgi

uQ,dY%

o Dalton W.S., Martz R., Lemberger L., Rodda B.E. & R.B. Forney. 1976.

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clinical

Pharmacology Therapeutics 19(3):300–309.

o Davis J.P. & H.H. Ramsey. 1949. Antiepileptic Action of Marijuana-Active

Substances. Federal Proceedings 8:284–285.

o Dewey W.L. 1986. Cannabinoid pharmacology. Pharmacological Reviews 38:

151–178.

o Di Marzo V. 2006. A brief history of cannabinoid and endocannabinoid

pharmacology as inspired by the work of British scientists. Trends in

Pharmacological Sciences 27: 134–140.

o Diaz J.L. 1977. Ethnopharmacology of sacred psychoactive plants used by

the Indians of Mexico. Annual Review of Pharmacology and Toxicology

17:647.

o Dwarakanath C. 1965. Use of opium and cannabis in the traditional systems

of medicine in India. Bulletin of Narcotics 17:15–19.

o El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D.,

Khan I., ElSohly M. & S. Ross. 2010. Antidepressant-like effect of Δ9-

tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa

(L). Pharmacology Biochemistry and Behavior 95(4):434–442.

o Elsohly M.A. & D. Slade. 2005. Chemical constituents of marijuana: the

complex mixture of natural cannabinoids. Life Sciences 78(5):539–548.

o Fernandez-Ruiz J. et al. 2007. Cannabinoid CB2 receptor: a new target for

controlling neural cell survival? Trends in Pharmacological Science 28:39–45.

o Fernandez-Ruiz J., Pazos M.R., Garcia-Arencibia M., Sagredo O. & J.A. Ramos.

2008. Role of CB2 receptors in neuroprotective effects of cannabinoids.

Molecular Cellular and Endocrinology 286:91–96.

o Gaoni Y. & R. Mechoulam. 1964. Isolation, structure and partial synthesis

of an active constituent of Hashish. Journal of American Chemical Society

86:1646–1647.

o Gerard C., Mollereau C., Vassart G. & M. Parmentier. 1990. Nucleotide sequence

of a human cannabinoid receptor cDNA. Nucleic Acids Research 18:7142.

o Giron L.M., Freire V., Alonzo A. & A. Caceres. 1991. Ethnobotanical

survey of the medicinal flora used by the Caribs of Guatemala. Journal of

Ethnopharmacology 34(2/3):173–187.

o Goutopoulos A. & A. Makriyannis. 2002. From cannabis to cannabinergics:

new therapeutic opportunities. Pharmacology & Therapeutics 95:103–117.

o Grierson G.A. 1894. The hemp plant in Sanskrit and Hindi literature. Indian

Antiquary September 260–262.

o Hampson A.J., Grimaldi M., Axelrod J. & D. Wink. 1998. Cannabidiol and

Delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings

of National Academy of Sciences in USA 95(14):8268–8273.

341

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!